Progesterone receptor (PR) expression and regulation of neural progenitor cell (NPC) proliferation was investigated using NPC derived from adult rat brain. RT-PCR revealed that PRA mRNA was not detected in rat NPCs, whereas membrane-associated PRs, PR membrane components (PGRMCs) 1 and 2, mRNA were expressed. Progesterone-induced increase in 5-bromo-2-deoxyuridine incorporation was confirmed by fluorescent-activated cell sorting analysis, which indicated that progesterone promoted rat NPC exit of G 0 /G 1 phase at 5 h, followed by an increase in S-phase at 6 h and M-phase at 8 h, respectively. Microarray analysis of cell-cycle genes, real-time PCR, and Western blot validation revealed that progesterone increased expression of genes that promote mitosis and decreased expression of genes that repress cell proliferation. Progesterone-induced proliferation was not dependent on conversion to metabolites and was antagonized by the ERK 1/2 inhibitor UO126. Progesterone-induced proliferation was isomer and steroid specific. PGRMC1 small interfering RNA treatment, together with computational structural analysis of progesterone and its isomers, indicated that the proliferative effect of progesterone is mediated by PGRMC1/2. Progesterone mediated NPC proliferation and concomitant regulation of mitotic cell cycle genes via a PGRMC/ERK pathway mechanism is a potential novel therapeutic target for promoting neurogenesis in the mammalian brain. (Endocrinology 150: 3186 -3196, 2009) E merging data indicate that progesterone (P 4 ) has multiple nonreproductive functions in the central nervous system (CNS) to regulate cognition, mood, inflammation, mitochondrial function, neurogenesis, regeneration, myelination, and recovery from traumatic brain injury (1-6). As a neurosteroid, P 4 can be generated de novo in the CNS (7-9). Developmentally, P 4 is synthesized in the CNS throughout the embryonic period in the pluripotential progenitor cells (10, 11) and reaches its highest concentration in late gestation (12). P 4 -regulated neural responses are mediated by an array of progesterone receptors (PRs), including the classic nuclear receptor (cPR) PR〈 and PRB, the seven-transmembrane domain-␤, and the membrane-associated 25-kDa protein (25-Dx) PR membrane components (PGRMCs) 1 and 2 (1).
Progesterone receptor (PR) expression and regulation of neural progenitor cell (NPC) proliferation was investigated using NPC derived from adult rat brain. RT-PCR revealed that PRA mRNA was not detected in rat NPCs, whereas membrane-associated PRs, PR membrane components (PGRMCs) 1 and 2, mRNA were expressed. Progesterone-induced increase in 5-bromo-2-deoxyuridine incorporation was confirmed by fluorescent-activated cell sorting analysis, which indicated that progesterone promoted rat NPC exit of G 0 /G 1 phase at 5 h, followed by an increase in S-phase at 6 h and M-phase at 8 h, respectively. Microarray analysis of cell-cycle genes, real-time PCR, and Western blot validation revealed that progesterone increased expression of genes that promote mitosis and decreased expression of genes that repress cell proliferation. Progesterone-induced proliferation was not dependent on conversion to metabolites and was antagonized by the ERK 1/2 inhibitor UO126. Progesterone-induced proliferation was isomer and steroid specific. PGRMC1 small interfering RNA treatment, together with computational structural analysis of progesterone and its isomers, indicated that the proliferative effect of progesterone is mediated by PGRMC1/2. Progesterone mediated NPC proliferation and concomitant regulation of mitotic cell cycle genes via a PGRMC/ERK pathway mechanism is a potential novel therapeutic target for promoting neurogenesis in the mammalian brain. (Endocrinology 150: 3186 -3196, 2009) E merging data indicate that progesterone (P 4 ) has multiple nonreproductive functions in the central nervous system (CNS) to regulate cognition, mood, inflammation, mitochondrial function, neurogenesis, regeneration, myelination, and recovery from traumatic brain injury (1) (2) (3) (4) (5) (6) . As a neurosteroid, P 4 can be generated de novo in the CNS (7) (8) (9) . Developmentally, P 4 is synthesized in the CNS throughout the embryonic period in the pluripotential progenitor cells (10, 11) and reaches its highest concentration in late gestation (12) . P 4 -regulated neural responses are mediated by an array of progesterone receptors (PRs), including the classic nuclear receptor (cPR) PR〈 and PRB, the seven-transmembrane domain-␤, and the membrane-associated 25-kDa protein (25-Dx) PR membrane components (PGRMCs) 1 and 2 (1) .
P 4 can promote cell proliferation in the breast (13) (14) (15) (16) and has both inhibitory and stimulatory effects in the uterus, depending on cell type, the regimen of treatment, whether PRA or PRB is expressed, the dose of 17␤-estradiol (E 2 ) and P 4 , and when in the cycle P 4 is administered (1) . As in the uterus, P 4 regulation of mitosis in the nervous system is complex. Results from multiple laboratories have indicated that P 4 regulates neural cell proliferation in both the peripheral and CNS (17) (18) (19) (20) . Tanapat et al. (21) have shown that ovariectomized rats treated with a high dose of E 2 showed enhanced hippocampal cell proliferation and subsequent exposure to P 4 antagonized E 2 -induced enhancement of cell proliferation after an initial increase. Interestingly, previous work from our laboratory demonstrated that 24 h exposure of embryonic d 18 rat hippocampal neurons to P 4 alone induced a 20% increase in [ 3 H]thymidine uptake, a phenomenon similar to that was observed after allopregnanolone (AP␣) exposure (1), indicating that P 4 alone may promote hippocampal progenitor cell proliferation and thereby act as a neurogenic agent.
Whereas P 4 is well characterized for its neuroprotective effects in the CNS (3, 5, (22) (23) (24) (25) (26) (27) and proliferative effects in the breast and uterus (1) , knowledge regarding its proliferative capability in the adult CNS, particularly in the neural stem/progenitor cell population, is limited. Thus, the first series of studies were designed to determine the neurogenic potential of P 4 in neural progenitor cells (NPCs) derived from adult rat dentate gyrus using cellular, morphological, biochemical, and genomic approaches. Furthermore, to determine the mechanism underlying P 4 's actions, a second series of studies were carried out to investigate signaling pathway and the effect of PGRMC1 small interfering RNA (siRNA) treatment on P 4 's effect.
Materials and Methods

Steroids
All steroids used in this study were purchased from Steraloids (Newport, RI). They are: pregn-4-ene-3,20-dione(progesterone), 5␣-pregnane-3,20-dione(5␣-dihydroprogesterone), 3␣-hydroxy-5␣-pregnan-20-one (allopregnanolone), 3␤-hydroxy-5␤-pregnan-20-one(epipreg-nanolone), 3␣-hydroxy-5␤-preg-nan-20-one(epiallopregnanolone), 3␤-hydroxy-5␣-pregnan-20-one, 3␣-hydroxy-5␤-meth-yl-5␣-pregnan-20-one(ganaxolone), 5␣-pregnan-3␤-ol, 5-pregnan-3␤-ol-20-one-3-sulfate(pregnanolone sulfate), 5␣-pregn-an-3␣,20␣-diol(allopregnanediol), and 5␣-pregnan-3␣,17,20␣-triol(allopregnanetriol).
Culture of rat NPCs
Rat NPCs derived from adult rat dentate gyrus (gift from Dr. Fred Gage, Laboratory of Genetics, The Salk Institute, La Jolla, CA) were provided as cryopreserved cells. They were cultured as described previously (28, 29) in DMEM/Ham's F-12 medium (1:1; Omega Scientific, Tarzana, CA) with 1% penicillin/streptomycin/amphotericin B (Invitrogen, Grand Island, NY), supplemented with N2 (1%; Invitrogen) and basic fibroblast growth factor (bFGF; 20 ng/ml; Invitrogen) in a humidified incubator (37 C and 5% CO 2 ). Cells were plated at a density of 2 ϫ e 6 cells/flask, 7.5-15 ϫ e 4 cells/well of 96-well plates, or 2-4 ϫ e 4 cells/cm 2 for chamber slides for analysis.
Immunocytochemical staining
To check the cell composition in the culture, rat NPCs (rNPCs) were plated onto four-well chamber slides and processed as described before (1) with the following primary antibodies (30, 31) : monoclonal antibody for neuronal class III␤-tubulin (NPC marker, 1:500; Covance Laboratories, Vienna, VA), monoclonal antibody for nestin (1:5000; Chemicon, Temecula, CA), monoclonal antibody for proliferating cell nuclear antigen (PCNA; 1:100; Zymed Laboratories, San Francisco, CA), and polyclonal antibody for PGRMC1 (32, 33) , followed by incubation with appropriate secondary antibodies conjugated with fluorescein isothiocyanate (1:200; Vector Laboratories, Burlingame, CA) or Texas Red (1:50; Vector Laboratories). Slides were mounted with 4Ј, 6-diamidino-2-phenylindole (DAPI)-containing mounting medium (Vector Laboratories), observed by Axiovert 200M fluorescent microscope (Zeiss, Oberkochen, Germany), and images were captured by SlideBook software (Intelligent Imaging Innovations, Denver, CO).
5-Bromo-2-deoxyuridine (BrdU) incorporation
Cell proliferation was evaluated by measuring the incorporation of BrdU in the S phase of the cell cycle. After 4 -6 h starvation (medium without supplements), rNPCs were loaded with 10 M BrdU in the presence or absence of bFGF and a different concentration of P 4 or other steroids in unsupplemented maintenance medium for 1 d. The cells were then processed using the method as described previously (34, 35) with kits purchased from Roche (Penzberg, Germany) and read with an Lmax microplate luminometer (Molecular Devices, Sunnyvale, CA). After subtracting the value of the blank (without BrdU loading), the results were analyzed using a one-way ANOVA, followed by a Neuman-Keuls post hoc test and presented as percentage increase vs. control.
Fluorescence-activated cell sorting (FACS) analysis
After 4 h of growth factor deprivation and incubation with vehicle (1ϫ e Ϫ6 ethanol) or 100 pM P 4 for indicated time, rNPCs were collected into Falcon 12-ϫ 75-mm tubes (polystyrene). After fixation with 100% ethanol and stained with propidium iodide for nuclear content, the cells were subjected to FACS analysis. In each sample, 1 ϫ e 5 cells were counted by LSRII flow cytometer (BD Biosciences, San Jose, CA); the numbers of cells under each phase of cell cycle were obtained, and analyzed using the embedded cell cycle analysis tool of the FlowJo program (Tree Star Inc., Ashland OR).
Gene-array assay
To analyze cell-cycle gene regulation, a commercially available targeted cDNA array of 112 cell-cycle regulatory genes and several housekeeping genes (Oligo GEArray rat cell cycle microarray; SABiosciences, Frederick, MD) was used to analyze cell-cycle gene regulation. After 6 h starvation, rNPCs were treated with or without 100 pM P 4 for 6 h, and total RNA was isolated using TRIzol reagent (Invitrogen) as described by the manufacturer. Ten micrograms of total RNA were reverse transcribed into biotin-16-deoxy-uridine 5-triphosphate-labeled single-strand cDNA and hybridized with nylon membrane, followed by incubation with alkaline phosphate-conjugated streptavidin. Chemiluminescence was visualized and captured by ChemiDoc XRS system (Bio-Rad, Hercules, CA). The intensity of the spots was extracted and data were analyzed using online GEArray expression analysis suite (http://geasuite.superarray.com/). Glyceraldehyde-3-phosphate dehydrogenase and Aldoa were used as internal controls. Bacterial plasmid (pUC18) was used as a negative control.
Real-time RT-PCR
Real-time RT-PCR was performed to validate the gene-array results. Total RNA was prepared as described above. cDNA synthesis and PCR amplification was carried out using iScript one-step RT-PCR kit with SYBR green (Bio-Rad) and primers as described before (34, 35) . RT-PCR and melting curve analysis were performed in multiplicate in optimized conditions as described by manufacturer. No other products were amplified because melting curves showed only one peak in each primer pair. Fluorescence signals were measured over 40 PCR cycles and ␤-actin was used as internal control. The cycle number (C T ) at which the signals crossed a threshold set within the logarithmic phase was recorded and the differences in cycle threshold (⌬⌬C T ) were used to analyze the gene expression in the P 4 -and vehicle-treated group: target gene P4 /target gene vehicle ϭ 2 -⌬⌬CT , where ⌬⌬C T ϭ (C T, target gene Ϫ C T, actin ) P4 Ϫ (C T, target gene Ϫ C T, actin ) vehicle .
Western blot analyses
After 6 h starvation, rNPCs were treated with or without 100 pM P 4 for 10 -12 h and processed for Western blot as described before (34, 35 
Computer modeling
All calculations were performed on a SGI Octane graphical workstation equipped with the IRIX 6.5 operating system (Silicon Graphics Inc., Mountain View, CA). An automated ligand-docking program, GOLD3.0 (Genetic Optimization for Ligand Docking, Cambridge, UK; Cambridge Crystallographic Data Center), was used to predict the binding modes of steroids into cPR binding site as described before (3, 34) . The three-dimensional structural coordinate data of human PR-ligandbinding domain complexes with P 4 was obtained from the Protein Data Bank (PDB entry: 1A28). The three-dimensional structures of steroids were constructed and energy minimized using the molecular modeling program InsightII 2000 (Accelrys Inc., San Diego, CA). GOLD offers several fitness functions, and GoldScore, which has been optimized for the prediction of ligand binding positions, was used in the present study.
PR competitive binding
The PR binding affinity and selectivity of the steroids were determined by a fluorescent polarization competitive binding assay using purified baculovirus-expressed human PR and a fluorescent progesterone ligand PL Red (Invitrogen) as described before (3, 34) . Polarization values were plotted against the logarithm of the test compound concentration and IC 50 value, the concentration of the test compound that displaces half of the PL Red from PR, was determined from the plot using a nonlinear least-squares analysis using Origin, version 8 (OriginLab Corp., Northampton, MA). Negative controls containing PR and PL Red (equivalent to 0% inhibition) and positive controls containing only free PL Red (equivalent to 100% inhibition) were included.
PGRMC1 siRNA treatment
Scrambled (catalog no. AM4611) or one of three predesigned PGRMC1 siRNAs (siRNA ID 253163, 253164, and 253165; Ambion, Austin, TX) was mixed with siPORT NeoFX transfection agent (Ambion) to yield a final concentration of 30 nm and siRNA transfection carried out according the siPORT NeoFX protocol outlined by Ambion. PGRMC1 siRNA no. 253163 and 253165 targeted sequences in the noncoding region (nucleotides 977-994 and 1329-1348, respectively). PGRMC1 siRNA no. 253164 targeted the polyA tail of PGRMC1 (nucleotides 1853-1870). After siRNA treatment for 24, 48, and 72 h, rNPCs were collected and processed for both immunocytochemically staining and Western blot analysis for PGRMC1 expression as described earlier. This pilot study revealed that optimal treatment paradigm was PGRMC1 siRNA 253163 for 48 h. For Western blot analysis, rNPCs were transfected with either scrambled or PGRMC1 siRNA 253163 for 48 h; starved for 4 h; treated with bFGF, vehicle, or 100 pM P 4 for 10 -12 h; and processed for Western blot analysis for PGRMC1, PCNA, and CDC2 expression level.
Statistical analysis
All experiments were repeated three to four times. When appropriate, data from each replicate were pooled and analyzed by either a Student t test if only two treatment groups were involved or by one-way ANOVA followed by Neuman-Keuls post hoc analysis if means of three or more groups were compared. Data displayed in graphs were reported as mean Ϯ SEM or fold change Ϯ SEM. P Ͻ 0.05 was considered to be significant, regardless of the statistical test used.
Results
Characterization of NPCs derived from adult rat dentate gyrus
The neural progenitor phenotype of rNPCs (gift of Dr. Fred Gage, Salk Institute, La Jolla, California) was verified by labeling for stem/progenitor cell marker, nestin (30, 34) , neural progenitor/neuronal marker, Tuj1 (31, 34) , and PCNA, a proliferating cell nuclear antigen associated with transition through S phase (34) . Cells were counterstained with DAPI for nuclei. Whereas rNPCs were nestin and Tuj1 positive, only a subset was in an active mitotic stage as indicated by PCNA expression (Fig. 1A) , which is consistent with previous reports (28, 29) . The expression profile of PRs in rNPCs was determined by RT-PCR for cPR, PGRMC1, and PGRMC2. RNA from rat whole brain was used as positive control, and a sample without reverse transcriptase (no RT) was used as a negative control. Results of RT-PCR indicated that both PGRMC1 and -2 were present in rNPCs, whereas cPR was not detectable (Fig. 1B) . This finding is consistent with previous reports that cPR is expressed in select cell populations in brain (1, 36) .
P 4 promotes rNPC proliferation in a dose-and time-dependent manner
BrdU chemiluminescence cell proliferation ELISA was conducted to determine the dose response and time course of P 4 -induced rNPC proliferation. To eliminate the contribution of growth factors in the culture medium, rNPCs were growth factor deprived for 4 h before exposure to P 4 (at concentrations ranging from 1 ϫ e Ϫ12 to 1 ϫ e Ϫ4 M), followed by BrdU ELISA. Our preliminary analyses indicated that 4 h starvation ensured sufficient cell synchronization and avoided loss of rNPC proliferative capability. P 4 induced a dose-dependent effect on BrdU incorporation in rNPCs ( Fig. 2A ) with an maximally effective concentration (EC 100 ) at 1 ϫ e Ϫ10 M (23.5 Ϯ 1.6% increase vs. vehicle, P Ͻ 0.05), an effect comparable with that induced by bFGF (20 ng/ml, 31.3 Ϯ 1.8% increase vs. vehicle, P Ͻ 0.01). P 4 -inducd BrdU incorporation exhibited an inverted-U-shape dose response with a decline in incorporation evident at 1 ϫ e Ϫ8 M, maximal at 1 ϫ e Ϫ5 M, and a significant inhibitory effect at 1 ϫ e Ϫ4 M. The optimal P 4 concentrations for inducing proliferation were 1 ϫ e Ϫ11 to 1 ϫ e Ϫ9 M. For subsequent experiments, 1 ϫ e Ϫ10 M (100 pM) was selected as the P 4 dose unless indicated otherwise.
To verify P 4 regulation on rNPC proliferation, cell cycle entry was analyzed using FACS analysis. After 4 h of growth factor deprivation and exposure to either vehicle or P 4 for indicated time period (Fig. 2B , a-c), rNPCs were collected and labeled with propidium iodide for DNA content analysis. To eliminate variations introduced across time, percent of cells within different cell cycle phases after P 4 exposure was normalized to vehicle control at the same time point and plotted as percent increase relative to con- A, Dose response of P 4 -induced proliferation in rat NPCs. Rat NPCs were starved for 4 h before treatment of P 4 (1 ϫ e Ϫ12 to 1 ϫ e Ϫ4 M) for 24 h, and cell proliferation was evaluated by BrdU chemiluminescence ELISA measuring BrdU incorporation. Ethanol was used as vehicle control (1 ϫ e Ϫ6 ). P 4 -induced cell proliferation showed a dose-dependent manner. Data were collected from three independent assays, analyzed using one-way ANOVA, followed by Neuman-Keuls post hoc test, and plotted as percentage increase vs. vehicle control. Data are mean Ϯ SEM and vehicle control was set to zero. *, P Ͻ 0.05 vs. control; **, P Ͻ 0.01 vs. vehicle control; ***, P Ͻ 0.001 vs. vehicle control. B, FACS analysis of 100 pM P 4 effect on rNPC cell cycle progression. Rat NPCs were starved for 4 h before treatment of P 4 (100 pM) or vehicle control (1 ϫ e Ϫ6 ethanol). Cells were harvested at time points indicated on the x-axis and processed for FACS analysis for DNA content and cell cycle progression. Ba, 100 pM P 4 effect on G 1 -phase population; Bb, 100 pM P 4 effect on Sphase population; Bc, 100 pM P 4 effect on G 2 /M-phase population. To eliminate the variation introduced by time, at each time point results from both groups were normalized to the vehicle control at the same time point, and vehicle control was set to one. Data were collected from three independent experiments and plotted as percent of rNPCs in each cell cycle in the P 4 -treated group vs. vehicle control (mean Ϯ SEM). *, P Ͻ 0.05 vs. vehicle control; **, P Ͻ 0.01 vs. vehicle control.
Endocrinology, July 2009, 150(7):3186 -3196 endo.endojournals.org 3189 trol for that time point (Fig. 2B, a-c , G 0 /G 1 phase, S phase, G 2 /M phase, respectively). P 4 promoted rNPC exit of G 0 /G 1 phase at 4 h (Fig. 2Ba, 70 .2 Ϯ 10.6% of vehicle, P Ͻ 0.05), induced a significant increase in cellular entry into S phase beginning at 6 h (218.6 Ϯ 36.2% of vehicle, P Ͻ 0.05) and extended until 8 h with a return to baseline at 9 h (Fig. 2Bb) . Parallel to the decrease in S phase population, a synchronized increase in G 2 /M phase population was observed at 8 h (124.3 Ϯ 15.2% of vehicle, P Ͻ 0.01), which ceased by 24 h. No statistically significant differences were observed between the control group and P 4 -treated group at 24 -72 h in G 0 /G 1 , S, or G 2 /M phase populations.
Results of the FACS analysis confirmed the BrdU dose-response data, indicating that at 100 pM P 4 is a potent mitotic agent in rNPCs. The timely coordinated changes in the G 0 /G 1 , S, and G 2 /M phase populations indicated that P 4 induced rNPC entrance and completion of a full cell cycle. P 4 induced a 1-fold increase in the S-phase population and a subsequent 24.3 Ϯ 15.2% increase in the M-phase population, indicating that only a portion of the S-phase population cells passed the S/M checkpoint and to give rise to new cells. Moreover, the amplitude in the change of the M-phase populations is consistent with results from previous BrdU dose-response experiment, where 100 pM P 4 induced a 23.5 Ϯ 1.6% increase in BrdU incorporation ( Fig. 2A) .
P 4 regulates gene expression of cellcycle proteins
P 4 -induced proliferation predicted its regulation of rNPC cell cycle gene expression. To determine P 4 regulation of cell cycle gene expression, RNA was extracted from rNPCs after 6 h P 4 exposure and processed for analysis of genes known to control cell proliferation. The 6-h time point was selected based on previous FACS results because it was the time when rNPCs exhibited the most robust increase in the S-phase cell population. Gene array analyses indicated that at the mRNA level, P 4 induced a significant up-regulation of genes that promote progression through the cell cycle and simultaneously decrease expression of the cell cycle inhibitor genes (Fig. 3A) . Robust increases occurred in genes that promote cell cycle progression, such as a 2-fold increase in cyclin-dependent kinase (CDK)-4 (promotes G 1 phase progression) and CDK2 (promotes G 1 /S phase progression), a 3-fold increase in cyclin A (promotes S/M phase transition), and more than a 2-fold increase in Cdc2, cyclin G1 and -2, and cyclin B (promote G 2 /M phase progression). In contrast, expression of inhibitors of cell cycle progression, such as CDKn2b, CDKn3, and Wee1, was significantly decreased. Several well-defined cell proliferation markers (37), including For gene array analysis, rNPCs were starved for 4 -6 h and then treated with vehicle or 100 pM P 4 for 6 h, followed by extraction of total RNA. For Western blot analysis, after 4 -6 h starvation, rNPCs were treated with bFGF, vehicle, or 100 pM P 4 for 24 h; collected; and processed for Western blotting. A, RNA was processed for DNA gene array analysis. Changes in gene expressions were grouped according to function. P 4 induced significant increase in genes that promote progression through the cell cycle and inhibited genes associated with exiting the cell cycle (summarized in supplemental Table 1 ). Two housekeeping genes (Aldoa and glyceraldehyde-3-phosphate dehydrogenase) were used as internal controls. Two blanks and pUC18 from bacterial plasmid were used as negative controls. Data were represented as percent change of mRNA expression in P 4 -treated rNPCs vs. control (mean Ϯ SEM) as determined by OD. Data were from three separate experiments and analyzed using both multivariant ANOVA statistical analysis and one-way ANOVA, followed by Neuman-Keuls post hoc test. *, P Ͻ 0.05 vs. vehicle control; **, P Ͻ 0.01 vs. vehicle control. B, Validation of the gene-array results by realtime RT-PCR. ⌬⌬C T was used to analyze the ratio of gene expression in the P 4 -treated group and vehicle control as follows: target gene P4 /target gene vehicle ϭ 2 -⌬⌬CT , where ⌬⌬C T ϭ (C T, target gene Ϫ C T, actin ) P4 Ϫ (C T, target gene Ϫ C T, actin ) vehicle . Data are depicted as percent increase of mRNA expression in P 4 -treated rNPCs vs. vehicle control (mean Ϯ SEM) from three separate experiments. Controls were set to zero and ␤-actin was used as internal control. *, P Ͻ 0.05 vs. vehicle control; **, P Ͻ 0.01 vs. vehicle control. C, Validation of the gene array results by Western blot analysis of two mitotic markers, PCNA and CDC2. Ethanol was used as vehicle control and bFGF was used as positive control. Data are depicted as percent increase of protein expression in P 4 -treated rNPCs vs. vehicle control (mean Ϯ SEM) from three separate experiments. Representative Western blotting membranes were shown at the bottom; ␤-actin was used as the loading control. *, P Ͻ 0.05 vs. vehicle control.
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Mcm5, Mcm7, and PCNA, showed a nearly 2-fold increase in expression. Furthermore, the gene expression data were divided into subgroups of genes known to promote or inhibit cell proliferation, and the data from each subgroup of genes were subjected to multivariate ANOVA (37) . Results of this analysis indicated a statistically significant effect of P 4 treatment on cyclins, CDKs, and CDK inhibitors (supplemental Table 1 , published as supplemental data on The Endocrine Society's Journals Online web site at http:// endo.endojournals.org).
Gene array results were further validated by real-time PCR (Fig. 3B) and Western blot analyses (Fig. 3C) . Real-time PCR was performed for five mRNAs coding for genes that promote transitions through the cell cycle, two genes that inhibit cell cycle progression, and two invariant genes. P 4 increased the mRNA expression level of cyclin A, cyclin B, PCNA, and Cdc2 and decreased the mRNA expression of Cdkn2c and Cdkn3 at magnitudes comparable with the gene array data. Western blot analyses indicated that P 4 increased PCNA and CDC2 protein level by 62.9 Ϯ 11.8 and 28.9 Ϯ 6.4%, respectively (P Ͻ 0.05 vs. vehicle), an effect comparable with that induced by bFGF (90.7 Ϯ 17.2 and 35.3 Ϯ 15.7%, respectively, P Ͻ 0.05 vs. vehicle). Together, these data indicated that P 4 promoted the expression of activators of cell-cycle progression, such as cyclins, CDKs, and PCNA and simultaneously down-regulating the CDK inhibitors. Moreover, S/M phase regulatory genes exhibited the most robust changes and confirmed results from previous FACS analysis, where 6 h was demonstrated to be the time point when S phase populations peak.
P 4 -induced proliferation of rNPCs is independent of its metabolites and requires ERK signaling
Based on previous findings from our group and others (34, 38, 39) , P 4 and its metabolites can act as mitotic agents. To determine whether P 4 metabolites contributed to or were required for P 4 -induced increase in proliferation, rNPCs were simultaneously exposed to P 4 and finasteride, which at nanomolar range effectively blocks the conversion of P 4 to 5␣-dihydroprogesterone and AP␣ (40) (Fig. 4A) . The concentration of finasteride was selected based on our previous investigation that 1 M was the maximally effective dose for inhibition of P 4 conversion without inducing inhibition of cell proliferation and/or cell death. Results from BrdU ELISA indicated no statistically significant difference between the P 4 alone and P 4 plus finasteride group at 24 h (Fig. 4B) , indicating that the proliferative effect of P 4 is not dependent on metabolism to its metabolites.
Our group earlier reported that P 4 activates the ERK signaling pathway to mediate its neuroprotective actions (27) , whereas AP␣ increased proliferation through activation of the ␥-aminobutyric acid (GABA) A receptor and L-type Ca 4 to its metabolites and required enzymes. B, Rat NPCs were starved for 4 -6 h and then treated with 100 pM P 4 alone or 100 pM P 4 ϩfinestaride for 24 h. Rat NPC proliferation was evaluated by BrdU chemiluminescence ELISA measuring BrdU incorporation. Comparative analysis showed no statistical significant difference between the P 4 -alone and P 4 ϩfinesteride group. Data were collected from at least three independent experiments and plotted as percentage increase of BrdU incorporation in the P 4 -treated rNPCs vs. vehicle control (mean Ϯ SEM). C, Rat NPCs were starved for 4 -6 h and treated with 100 pM P 4 alone or in combination of ERK inhibitor UO126 or in combination of the inactive analog of UO126 (UO124). After 24 h rNPC proliferation was evaluated by BrdU chemiluminescence ELISA measuring BrdU incorporation. P 4 -induced cell proliferation could be totally abolished by ERK inhibitor UO126, and UO124 did not show significant effect. Data were collected from five independent experiments and plotted as percentage increase of BrdU incorporation vs. vehicle control (mean Ϯ SEM). **, P Ͻ 0.01 vs. vehicle control; ***, P Ͻ 0.001 vs. vehicle control; † †, P Ͻ 0.01 P 4 alone vs. P 4 ϩUO126. D, Rat NPCs were starved for 4 -6 h and treated with 100 pM P 4 alone or in combination of GABA A receptor antagonist bicuculline or in combination of L-type calcium channel blocker nifedipine. After 24 h rNPC proliferation was evaluated by BrdU chemiluminescence ELISA measuring BrdU incorporation. The proliferative effect of P 4 was not blocked by bicuculline or nifedipine. Data were collected from three independent experiments and plotted as percentage increase of BrdU incorporation vs. vehicle control (mean Ϯ SEM). *, P Ͻ 0.05 vs. control; **, P Ͻ 0.01 vs. control. Endocrinology, July 2009, 150 (7):3186 -3196 endo.endojournals.orgchannel (34) . To determine the signaling pathway required for P 4 -induced proliferation, BrdU ELISA was carried out in rNPCs exposed to pharmacological agents to interrogate the ERK and Ca 2ϩ -dependent systems. At 24 h, P 4 induced a cumulative increase of 26.3 Ϯ 1.6% (P Ͻ 0.001 vs. vehicle) in rNPC proliferation, an effect that was abolished by the ERK inhibitor UO126 and not significantly affected by the same dose of the inactive analog of UO124 (P ϭ 0.17) (Fig. 4C) . Application of neither bicuculline (GABA A receptor antagonist) nor nifedipine (L-type Ca 2ϩ channel blocker) inhibited P 4 -induced rNPC proliferation (Fig. 5D) . Together, results of these analyses indicate that P 4 -induced rNPC proliferation is dependent on the ERK signaling pathway.
The proliferative effect of progesterone is independent of cPR binding affinity
To determine the structure and activity relationship for P 4 -induced rNPC proliferation, BrdU ELISA was used to compare the proliferative effects of P 4 and its structural analogs at the same concentrations (Fig. 5A) . Results indicated that at 24 h, P 4 , AP␣, and ganaxolone were equally efficacious at their EC 100 concentrations, with EC 100 values being 1 ϫ e Ϫ10 M, 1 ϫ e Ϫ8 , and 1 ϫ e Ϫ5 M, respectively. Epiallopregnanolone exhibited moderate proliferative efficacy, whereas epipregnanolone, allopregnanetriol, pregnanolone sulfate, 5␣-dihydroprogesterone, and 5␣-pregnan-3␤-ol were ineffective. Additionally, allopregnandiol induced a significant decrease in BrdU incorporation in a dose-dependent manner, consistent with its effect on rNPC differentiation (34) . AP␣, epiallopregnanolone, and epipregnanolone are three molecules that differ in the position of the 3-hydroxyl and 5-hydrogen groups. Change in one or both ␣-positioned group(s) to the ␤-position results in a decrease in the proliferative efficacy (epiallopregnanolone) and eventually resulting in ineffectiveness (epipregnanolone). Computational modeling revealed three critical structural features: the 18th ketone group position, the ␣-positioned fifth hydrogen, and the at the third hydroxyl group (Fig. 5B) . Importantly, these structural features matched with the binding features required for PGRMC1 (41) . A parallel computational modeling of the binding modes of tested molecules with cPR, together with a fluorescent polarization competitive cPR binding assay, indicated that there is no clear association between the binding affinity to cPR and proliferative capabilities of these neurosteroids (see supplemental Table 2 ). Collectively, these data indicated no clear link between cPR activation and rNPC proliferation.
PRGMC1 is necessary and sufficient for P4-induced rNPC proliferation
Evidence so far has excluded the potential role of cPR in mediating P 4 -induced cell proliferation, leaving PGRMC1 as a possible candidate. To determine the correlation between PGRMC1 and rNPC proliferation, double labeling of PGRMC1 and PCNA was conducted in rNPCs 10 -12 h after P 4 treatment. Immunocytochemical analysis revealed a subpopulation of PGRMC1-positive rNPCs (Fig. 6A) . Furthermore, only PGRMC1-positive cells were PCNA positive after P 4 exposure (Fig. 6A) , indicating that PGRMC1 was correlated with P 4 -induced rNPC proliferation.
To further determine whether PGRMC1 was required for P 4 -induced proliferation, siRNA was introduced to knock down PGRMC1 expression in the rNPCs. Among all the siRNAs tested, PGRMC1 siRNA 253163 was determined to be most efficient, with a 68.1 Ϯ 3.0% (P Ͻ 0.05 vs. vehicle) knockdown rate compared with scrambled siRNA control (Fig. 6B-II) . Knockdown of PGRMC1 had no effect on the basal level proliferation in rNPCs under maintenance condition when bFGF is present (28, 29) , as demonstrated by the constant PCNA and CDC2 protein expression across treatment groups (Fig. 6B, II  and III) . To assess the effect of PGRMC1 depletion, rNPCs were treated with either scrambled or PGRMC1 siRNA. After 48 h, rNPCs were treated with bFGF, vehicle, or P 4 and the ability of P 4 to promote proliferation was determined by PCNA and CDC2 protein expression level. In response to P 4 , PCNA and CDC2 expression increased by 63.9 Ϯ 20.8 and 37.5 Ϯ 7.6%, 5 . The proliferative effect of P 4 is independent of cPR binding affinity. Rat NPCs were starved for 4 h before treatment of P 4 and its analogs (1 ϫ e Ϫ12 to 1 ϫ e Ϫ4 M) for 24 h, and cell proliferation was evaluated by BrdU chemiluminescence ELISA measuring BrdU incorporation. Ethanol was used as vehicle control (1 ϫ e Ϫ6 ). A, P 4 and its structural analogs exhibited varied effects on rNPC proliferation. P 4 , AP␣, and ganaxolone were equally efficacious and epiallopregnanolone exhibited moderate proliferative effect. Epipregnanolone, allopregnanetriol, pregnanolone sulfate, 5␣-dihydroprogesterone, and 5␣-pregnan-3␤-ol were ineffective, whereas allopregnandiol induced a significant decrease in BrdU incorporation. Data were collected from three independent assays, analyzed using one-way ANOVA, followed by Neuman-Keuls post hoc test, and plotted as percentage increase vs. vehicle control (mean Ϯ SEM). *, P Ͻ 0.05 vs. vehicle control; **, P Ͻ 0.01 vs. vehicle control; ***, P Ͻ 0.005 vs. vehicle control. B, Structure activity relationship analysis of the proliferative ability of the steroids and their binding affinity to cPR. Results were collected from three independent PR-binding assays and summarized in supplemental Table 2 . As highlighted in the chemical structure of AP␣, three structural features were revealed to be critical for P 4 and its analog-induced proliferation in rNPCs: the ketone group at the 18 position, the ␣-positioned hydrogen at the 5 position, and the hydroxyl group at the 3 position.
respectively (P Ͻ 0.05 vs. vehicle). Introduction of siRNA against PGRMC1 resulted in a 59.7 and 84.0% decrease in P 4 -induced PCNA and CDC2 expression compared with the scrambled siRNA-treated group (Fig. 6C II and III, P Ͻ 0.05). Notably, knockdown of PGRMC1 remarkably decreased basal expression level of PCNA and CDC2 mitotic markers in rNPCs (Fig. 6C , II and III, P Ͻ 0.05), suggesting that PGRMC1 could be involved in signaling pathways regulating constitutive proliferation in rNPCs. These results further confirmed that knockdown of PGRMC1 specifically and significantly decreased P 4 -induced rNPC proliferation. Collectively, these data demonstrated that PGRMC1 is necessary and sufficient for P 4 -induced rNPC proliferation.
Discussion
Results of the present study demonstrate for the first time that P 4 increases proliferation of adult rNPCs in a dose-dependent manner. P 4 significantly increased the expression of genes required for progression through the cell cycle and inhibited expression of genes involved in cell cycle repression. Mechanistic analyses revealed that rNPC proliferation was a direct effect of P 4 and not exerted via its metabolites. Furthermore, P 4 -induced rNPC proliferation is dependent on the ERK/MAPK signaling pathway and is mediated by the membrane PR, PGMRC1. P 4 increased proliferation of rNPC from female adult rat hippocampus with maximal proliferative efficacy within the picomolar/ nanomolar range, which was reversed at higher micromolar range. In adult female rat, P 4 plasma levels range from 1 to 200 nM, and the concentration of P 4 in the brain is thought to closely follow circulating plasma levels (42, 43) . The effective concentration of P 4 is comparable with that of both plasma and brain, indicating the physiological relevance of P 4 's mitotic effect. Other groups have reported that P 4 regulates cell proliferation in both peripheral and central nervous system at nanomolar/micromolar ranges (17, 18, 20) . The discrepancies between the effective P 4 concentrations across studies may arise from varied P 4 responsiveness in different cell and tissue types. Indeed, hippocampal cells are more sensitive than cerebellum cells in response to P 4 -induced neuroprotective effects, with minimally effective concentrations within the nanomolar to micromolar range, respectively (1). Alternatively, P 4 may promote cell proliferation via different signaling pathways (1) as well as conversion to its metabolites (38) , leading to the different requirements in P 4 concentrations. The mitotic efficacy of P 4 was comparable to bFGF as evidenced by BrdU incorporation and regulation of the expression PCNA and CDC2, two well-defined and commonly used markers for cell proliferation (44) . PCNA is a marker for cells in early G 1 /S phase of the cell cycle and acts as a homotrimer to increase the processing of leading strand synthesis during DNA replication. CDC2/CDK1 is the catalytic subunit of the protein kinase complex M-phase promoting factor and is required for the G 2 /M phase transition (44) . Both PCNA and CDC2 expression were up-regulated after P 4 treatment, indicating that P 4 promoted rNPC entry into and completion of the cell cycle. Importantly, FACS analysis indicated that P 4 -induced DNA synthesis did not persist beyond 24 h, indicating that P 4 -responsive rNPCs traversed the cell cycle but did not remain in a proliferative state and thus P 4 , in vitro, did not induce prolonged or uncontrolled proliferation. P 4 may increase proliferation by speeding up cell cycle in the same cell population or recruiting more cells into cell cycle. Immunocytochemical analyses argued for the latter because only PGMRC1ϩrNPCs entered into Gs as a result of P 4 exposure; however, the possibility of accelerated cell cycle cannot be ruled out at this point.
We previously demonstrated that AP␣ increased NPC proliferation at an optimal dose of 100 nM (34) , whereas in the present study, P 4 exhibited an optimal concentration 1000 times lower than that of AP␣. It was thus unlikely that P 4 promoted proliferation via its metabolites. This was confirmed by application of finasteride, which showed no significant effect on P 4 's action. However, recent studies from other groups suggested an effect of P 4 metabolites (39, 45) . The discrepancy may due to the differences between embryonic NPCs and adult NPCs because polysialic acid neural cell adhesion molecule-positive progenitors were obtained from postnatal d 1 rat (45) . The signaling machinery for P 4 and AP␣ may be differently expressed in embryonic vs. adult NPCs. Alternatively, differences may arise from targeting neuronal vs. glial progenitor cells. The rNPCs are proneurogenesis have an increasing proportion of neuronal-like cells in long-term cultures (Ͼ200 d in vitro) (46) , whereas the prostate-specific antigen-neural cell adhesion molecule-positivepositive progenitors have a default differentiation to glial lineages (45) , and their proliferation may be more relevant to gliogenesis. Although P 4 and AP␣ may be present at the same time in NPCs as evidenced by the presence of 5␣-reductase (47), it is possible that they exhibit distinct binding kinetics to their targets and exert effects at different time points.
Although cPR has been reported to respond to P 4 in a nongenomic fashion via activating second messenger signaling cascades (26, 27, 48) , results from RT-PCR, steroid specificity analysis, and computational modeling ruled out its involvement in P 4 -induced proliferation. Specifically the potent cPR agonist, 5␣-dihydroprogesterone and epipregnanolone (49) , showed no effect on rNPC proliferation. In fact, multiple groups have reported P 4 effects in the CNS of cPR knockout mice (50) , pointing to the involvement of other receptors in response to P 4 . PRGMC1 is reported to mediate the response to P 4 in murine embryonic sensory neurons (51), granulose cells (33) , and neonatal rat Purkinje cells (52) , suggested to play a role in promoting neonatal dendritic growth, spinogenesis, and synaptogenesis. Our study indicated that siRNA-induced depletion of PGRMC1 significantly and specifically reduced P 4 -increased cell proliferation. These findings together with the computational modeling analyses indicated that PGRMC1 was the key mediator of P 4 -induced rNPC proliferation. siRNA depletion of PGRMC1 was not absolute and left a residual 31.8% expression and thus could explain the residual P 4 induction of proliferation markers. Alternatively, other P 4 -binding receptors such as the seven-transmembrane domain-␤ (1) could account for the residual P 4 -induced proliferation, although expression of such receptors has not been documented in rNPCs. Knockdown of PGRMC1 significantly decreased basal expression level of mitotic markers in rNPCs, indicating that P 4 requires PGRMC1 to induced proliferation, whereas PGRMC1 may respond to factors other than P 4 to regulate rNPC proliferation. Indeed, PGRMC1 has been shown to be activated by heme and steroid/sterol ligands and SH2-and SH3-domain proteins as well as kinases, implicating a possible function for PGRMC1 in regulating protein interactions and intracellular signal transduction (1, 53) , which may be crucial for proliferation.
The underlying mechanism for the correlation between elevated expression of PGRMC1 and cell proliferation remains unclear. One potential explanation is the neurotrophic activity of the secreted PGRMC1 family member neudesin, which directly stimulates MAPK and Akt signaling to promote proliferation and neuronal differentiation in mouse NPCs (54, 55) . Our results indicating that P 4 -induced, PGRMC1-dependent cell proliferation required ERK signaling pathway are consistent with these earlier findings suggesting that P 4 -induced proliferation via the ERK signaling pathway generalizes to other cell systems. P 4 is well known for its neuroprotective effects within the CNS and has been used as a myelinating agent and as a treatment for traumatic brain (4). In the aged brain, both the pool of neural stem cells and their proliferative potential are markedly diminished (56 -58) . The discovery that P 4 could promote adult rNPC proliferation highlights the potential use of P 4 as a regenerative agent in adult brain. Indeed, several studies report that administration of P 4 could improve cognitive performance in the aging mouse when compared with control groups (59 -61) . Together with our present data, these findings suggest a promising strategy for promoting neurogenesis in the adult brain. Furthermore, the finding that estrogen receptor and PGRMC1 were mutually exclusive in breast tumor sections, and PGRMC1 labeling increased in hypoxic areas of the tumor (62, 63) suggests that   FIG. 6 (cont) . for 10 -12 h and processed for Western blot analysis. PGRMC1 siRNA significantly and specifically reduced the expression of PGRMC1 (C, I), blocked the increase of PCNA (C, II) and CDC2 (C, III) in response to P 4 , and had no significant effect on bFGF-induced mitotic marker expression. Representative Western blotting membranes were shown (C, IV); ␤-actin was used as loading control. Results were collected from three independent experiments and plotted as percent increase vs. vehicle control (mean Ϯ SEM). *, P Ͻ 0.05; **, P Ͻ 0.01; §, P Ͻ 0.05 between vehicle control in the control group and PGRMC1 siRNA 253163 group; ᐉ, P Ͻ 0.05 vs. P 4 treatment in scramble control group; †, P Ͻ 0.05 vs. bFGF treatment in PGRMC1 siRNA 253163 group.
targeting PGMRC1 may be a novel approach to promote proliferation in brain and avoid tumorogenic effects in estrogen receptor-positive cells.
